HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients

CompletedOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions
Covid19
Interventions
GENETIC

Expression of receptors and activating proteases

Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19

GENETIC

Polymorphism of the HSD3B1

Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)

Trial Locations (2)

6500

Oncology Institute of Southern Switzerland (IOSI), Bellinzona

6900

Clinica Luganese Moncucco, Lugano

All Listed Sponsors
collaborator

Institute of Oncology Research (IOR)

UNKNOWN

collaborator

Istituto Cantonale di Patologia

OTHER

lead

Ricardo Pereira Mestre

OTHER

NCT04516850 - HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients | Biotech Hunter | Biotech Hunter